3002120099
Other anti sera and other blood samples
Bottom line tax number generated by splitting anti-cancer drugsDeclaration Elements
0: Brand type
1: Export benefits situation
2: Purpose:
3: Processing technology
4: Is the dosage prescribed
5: Is it retail packaging
6: Has this batch been approved for registration and listing in China
7: Ingredients
8: Source:
9: Brand (Chinese or foreign name)
10: Model number
11: Packaging specifications
12:GTIN
13:CAS
14: Other
Customs Control Code
Customs Clearance Voucher for Entry Goods
Customs Clearance Voucher for Exit Goods
CIQ Category Code
Entry Animal and Plant, Animal and Plant Products Quarantine
Exit Animal and Plant, Animal and Plant Products Quarantine
On behalf of Entry Health Quarantine(或：Agent for Entry Health Quarantine)
On behalf of Exit Health Quarantine(或：Agent for Exit Health Quarantine)
By each trade agreement
RCEP
Directory
ChinaChina HS CodeSection 6Products of the chemical industry and related industries30medicine3002Human blood; Animal blood products used for disease treatment, prevention or diagnosis; Anti serum, other blood samples, and immune products, whether modified or processed through biological processes; Vaccines, toxins, cultured microorganisms (excluding yeast) and similar products; Cell cultures, whether modified or not300212Antiserum and other blood samples30021200Antiserum and other blood samples3002120099Other anti sera and other blood samplesCIQ
Other anti serum or other blood samples (pig blood powder, tax identification number generated from splitting anti-cancer drugs)
Other anti serum or other blood samples (bovine blood powder, a safety net generated from the splitting of anticancer drugs)
Other anti serum or other blood samples (sheep blood powder, a safety net generated from the splitting of anticancer drugs)
Other anti serum or other blood samples (deer blood powder, a safety net generated by splitting anti-cancer drugs)
Other anti serum or other blood samples (poultry blood powder, tax identification number generated from splitting anti-cancer drugs)
Other anti serum or other blood samples (other animal blood powder, tax identification number generated from splitting anti-cancer drugs)
Other anti serum or other blood samples (other blood powder from cloven hoofed animals, generated by splitting anti-cancer drugs)
Other anti serum or other blood samples (other wild clove hoofed animal blood powder, tax identification number generated from splitting anti-cancer drugs)
Other anti sera and other blood samples (due to the tax identification number generated by the splitting of anti-cancer drugs) (other chemical products)
Other anti sera and other blood samples (other human blood products)
Other anti sera and other blood samples (generated by the splitting of anticancer drugs) (collected clinically, including Class I pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by the splitting of anticancer drugs) (collected clinically, including Class II pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (collected clinically, including three types of pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (collected clinically, including four types of pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (collected clinically, including pathogenic microorganisms of newly emerging infectious diseases or re emerging infectious diseases outside the list)
Other anti sera and other blood samples (due to the identification number generated by splitting anti-cancer drugs) (collected clinically, including parasites)
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (collected clinically and screened negative for blood borne pathogens)
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (commercialized including Class I pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (commercialized including Class II pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (commercialized including three types of pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (commercialized including four types of pathogenic microorganisms listed in the "List of Human Infectious Pathogenic Microorganisms")
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (commercialized and tested negative for blood borne pathogens)
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (blood samples of special blood types donated for clinical use)
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (human anti sera under drug management)
Other anti sera and other blood samples (due to the identification number generated by splitting anti-cancer drugs) (anti sera from other individuals)
Other anti serum and other blood samples (due to the tax identification number generated by splitting anti-cancer drugs) (other human blood samples)
Other anti sera and other blood samples (generated by splitting anti-cancer drugs) (used for polyclonal antibodies in human medicine and life science related fields)
Other anti sera and other blood samples (due to the identification number generated by splitting anti-cancer drugs) (according to the drug management personnel's plasma protein products (albumin, globulin, fibrinogen))
Disclaimer
The data on this page is sourced from publicly available information and is for reference only. It has no legal effect. Actual procedures should be based on the latest Import and Export Tariff Schedule and relevant laws and regulations issued by the General Administration of Customs.
